Subtype
Breast Carcinoma
CI-CAN-00000594Explore in graph →
873 active trials12 approved drugs113 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000594Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (365)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06433804 | Clinicopathological Parameters of HER2 Low Breast Cancers | completed | — | 70 | Vardhman Mahavir Medical College And Safdarjung HospitalOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT04752267 | 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases | completed | Early Phase 1 | 10 | University of Southern CaliforniaOTHER | 1 | May 24, 2024 |
| clinicaltrials |
| NCT03256344 | Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases | completed | Phase 1 | 36 | AmgenINDUSTRY | 6 | May 14, 2024 | clinicaltrials |
| NCT01703520 | Finasteride (MK-0906) and Male Breast Cancer - A Register-Based Nested Case-Control Study (MK-0906-162/2003.021). | completed | — | 575,216 | Organon and CoINDUSTRY | 0 | May 10, 2024 | clinicaltrials |
| NCT04742959 | Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 203 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT03330561 | PRS-343 in HER2-Positive Solid Tumors | completed | Phase 1 | 85 | Pieris Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 22, 2024 | clinicaltrials |
| NCT03650348 | PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors | completed | Phase 1 | 41 | Pieris Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 22, 2024 | clinicaltrials |
| NCT04087057 | Barriers Associated With Timely Adjuvant Chemotherapy Administration in Patients With Invasive Breast Cancer | completed | — | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT06090630 | MR Correlated Spectroscopic Imaging for Diagnosing Breast Cancer | completed | Early Phase 1 | 83 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05234021 | HER2-directed Biosimilar in Breast Cancer: Real World ePRO(OGIPRO) | completed | — | 52 | OnkoZentrum Zürich AGOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT04535323 | Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast Cancer | completed | Phase 1 | 20 | Mayo ClinicOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT02996825 | Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer | completed | Phase 1 | 44 | City of Hope Medical CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04177108 | A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer | completed | Phase 3 | 242 | Hoffmann-La RocheINDUSTRY | 37 | Mar 27, 2024 | clinicaltrials |
| NCT04613674 | A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) | completed | Phase 3 | 441 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 27, 2024 | clinicaltrials |
| NCT03125902 | A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)(IMpassion131) | completed | Phase 3 | 653 | Hoffmann-La RocheINDUSTRY | 24 | Mar 26, 2024 | clinicaltrials |
| NCT04134884 | Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer | completed | Phase 1 | 34 | Kathy MillerOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT05946759 | Reoperation Rate in Breast-Conserving Surgery Using Confocal Histolog® Scanner for Intraoperative Margin Assessment(SHIELD) | completed | N/A | 54 | SamanTree Medical SAINDUSTRY | 1 | Mar 21, 2024 | clinicaltrials |
| NCT03007979 | Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer | completed | Phase 2 | 55 | Washington University School of MedicineOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT02648477 | Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer | completed | Phase 2 | 30 | City of Hope Medical CenterOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT05458401 | EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan(EUROPA T-DXd) | completed | — | 256 | Daiichi SankyoINDUSTRY | 3 | Mar 15, 2024 | clinicaltrials |
| NCT06309459 | Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma | completed | — | 40 | Kahramanmaras Sutcu Imam UniversityOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT05112536 | Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer | completed | Phase 2 | 24 | G1 Therapeutics, Inc.INDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT00096434 | Sorafenib in Treating Patients With Metastatic Breast Cancer | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Mar 7, 2024 | clinicaltrials |
| NCT02620280 | Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1(NeoTRIPaPDL1) | completed | Phase 3 | 278 | Fondazione MichelangeloOTHER | 7 | Mar 6, 2024 | clinicaltrials |
| NCT03752723 | Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899) | completed | Phase 1 / Phase 2 | 84 | Genexine, Inc.INDUSTRY | 1 | Mar 5, 2024 | clinicaltrials |
| NCT02476539 | Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer | completed | Phase 1 | 28 | Tianjin Hemay Pharmaceutical Co., LtdINDUSTRY | 1 | Mar 1, 2024 | clinicaltrials |
| NCT00618657 | Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting | completed | Phase 2 | 127 | University of California, IrvineOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06040593 | Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer | completed | — | 927 | Daiichi SankyoINDUSTRY | 1 | Feb 26, 2024 | clinicaltrials |
| NCT02971761 | Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer | completed | Phase 2 | 18 | City of Hope Medical CenterOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03853707 | Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer | completed | Phase 1 / Phase 2 | 28 | City of Hope Medical CenterOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT02456857 | Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative | completed | Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT04667481 | Adaptive Training Exercise Programs for Improving Cardiorespiratory Fitness After Breast Cancer Treatment, The ACTIVATE Trial(ACTIVATE) | completed | N/A | 27 | University of WashingtonOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT03564782 | Examining Bioactivity of PVSRIPO in Invasive Breast Cancer | completed | Early Phase 1 | 5 | Istari Oncology, Inc.INDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT03012230 | Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer | completed | Phase 1 | 12 | Mayo ClinicOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT05161507 | Magseed and Magtrace Localization for Breast Cancer | completed | — | 70 | University Hospital OstravaOTHER | 1 | Jan 26, 2024 | clinicaltrials |
| NCT03657069 | Blossom Smart Expander Technology in Breast Reconstruction in Participants With Breast Cancer Undergoing Mastectomy | completed | N/A | 11 | Stanford UniversityOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT06205394 | Improving The Breast Cancer Care Delivery Model for Sex and Gender Minority Survivors, Intended for SGM Study | completed | — | 28 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT03454451 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | completed | Phase 1 | 117 | Corvus Pharmaceuticals, Inc.INDUSTRY | 2 | Dec 21, 2023 | clinicaltrials |
| NCT02834403 | L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients | completed | Phase 1 / Phase 2 | 37 | The Methodist Hospital Research InstituteOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT03831711 | 68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer | completed | Phase 1 / Phase 2 | 5 | Andrei IagaruOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT02636582 | Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer | completed | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 5, 2023 | clinicaltrials |
| NCT01142401 | Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer | completed | Phase 2 | 118 | National Cancer Institute (NCI)NIH | 1 | Nov 27, 2023 | clinicaltrials |
| NCT02672475 | Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer | completed | Phase 1 | 29 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT01219075 | Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer | completed | N/A | 110 | University of Southern CaliforniaOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT02527434 | Study of Tremelimumab in Patients With Advanced Solid Tumors | completed | Phase 2 | 64 | AstraZenecaINDUSTRY | 5 | Nov 15, 2023 | clinicaltrials |
| NCT06107790 | Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer | completed | Phase 3 | 570 | Zhejiang Hisun Pharmaceutical Co. Ltd.INDUSTRY | 1 | Oct 30, 2023 | clinicaltrials |
| NCT03197935 | A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer(IMpassion031) | completed | Phase 3 | 333 | Hoffmann-La RocheINDUSTRY | 13 | Oct 26, 2023 | clinicaltrials |
| NCT03358017 | Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer(YAPPETIZER) | completed | Phase 2 | 54 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT01622868 | Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer | completed | Phase 2 | 143 | National Cancer Institute (NCI)NIH | 3 | Oct 17, 2023 | clinicaltrials |
Data updated 23 days agoSource updated May 30, 2024source: clinicaltrials